US FDA Drops Plan To Simplify Pharmaceutical Plant Reporting
Executive Summary
Industry complained draft guidance would have made manufacturing establishment information harder to report, not easier.
You may also be interested in...
FDA Guidance Clarifies Facility Requirements
The US FDA has made a renewed effort to clarify the types of manufacturing facilities that need to be listed on the Form FDA 356h and Module 3 of the CTD in submissions. Often reviewers find this information missing, which can result in a refuse to file action.
US FDA Details Facilities That NDAs, ANDAs Should Note
The US FDA has made a renewed effort to clarify the types of manufacturing facilities that need to be listed on the Form FDA 356h and Module 3 of the CTD in submissions. Often reviewers find this information missing, whicn can result in a refuse to file action.
FDA Looks To Strengthen, Speed Drug Reviews With Flow Of Quality Data
Lift the burden of paper on drug quality reviews and the pace of innovation is no longer a problem for structural engineers or couriers – or even print or electronic document rooms. The focus at the US FDA is now on enabling direct transmission and analysis of critical quality data.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: